ArticleWorld journal of surgical oncology2022

B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.

Ying Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.